^
Association details:
| Biomarker: | ALK V3a |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | ALK inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Published date:
12/03/2020
Excerpt:
A total of 84 patients received ALK inhibitor(s) treatment while they were in advanced stage….Of note, patients with ALK V3a/b exhibited a worse OS (HR 4.24 [95% CI 1.01–17.79], P = 0.049)…
DOI:
10.1038/s41598-020-78152-1
